Center on Health Equity & Access
Clinical
Health Care Cost
Health Care Delivery
Insurance
Policy
Technology
Value-Based Care

Biosimilars Cardiorenalmetabolic Dermatology Gastroenterology Hematology Hepatology Immunology Infectious Disease Mental Health Neurology Obesity Oncology Ophthalmology Pulmonology Rare Disease Respiratory Rheumatology Women's Health

Free In-Person Regional Events Focused on Oncology and Population Health

Biosimilars Center on Health Equity & Access Digital Health Formulary Gene Therapy Guidelines Health Care Administration Health Care Cost Health Care Delivery Insurance Policy Population Health Product Approvals and Launches Technology Value-Based Care

All Coverage Event Coverage Interviews News

AJMC Journals Anniversary Author Forms Authors Nominate a Rising Leader Submit a Manuscript

AJMC® Roundtable: Defining Value for the Treatment of Brain Metastases in HER2+ Metastatic Breast Cancer

home / publications / supplement / ajmc-roundtable-defining-value-for-the-treatment-of-brain-metastases-in-her2-metastatic-breast-c

AJMC® Roundtable: Defining Value for the Treatment of Brain Metastases in HER2+ Metastatic Breast Cancer

August 16th 2021

This supplement was developed in conjunction with and sponsored by Seagen Inc. The supplement is based upon a roundtable meeting with A. Gajra, W. J. Gradishar, K. Kalinsky, M. Lopes, R. L. Mahtani, S. Soefje, N. Vasan, and R. D. Rao, who received a fee from Seagen Inc. The American Journal of Managed Care® also received a fee from Seagen Inc for providing editorial support.

Editorial Boards

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences
AJMC®
All rights reserved.